Background-Monitoring anticoagulation with activated clotting time (ACT) has been proposed to reduce ischemic or bleeding events. However, the value of using ACT to improve outcomes is uncertain. This study sought to determine the relationship between ACT and outcomes during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) treated by unfractionated heparin with GPIs (glycoprotein IIb/IIIa inhibitors). Methods and Results-From the randomized TAO trial (Treatment of Acute Coronary Syndromes With Otamixaban), we analyzed the value of ACT to predict ischemic and bleeding outcomes in the 3275 patients receiving unfractionated heparin plus eptifibatide. Ischemic and safety outcomes were analyzed according to ACT to determine the best threshold. Median peak ACT was 225 s. There was no correlation (r=−0.02; P=0.24) between the unfractionated heparin dose received and the ACT value before percutaneous coronary intervention. There was no evidence of a nonlinear association between ACT and either ischemic or bleeding events (P=0.66; P=0.07). No threshold was found to predict ischemic complications. Conversely, increased bleeding was observed with ACT >230 s with an optimal threshold of ACTs ≥250 s (4.53% versus 6.17%; odds ratio, 1.46; 95% confidence interval, 1.04-2.06; P=0.028). This optimal threshold varied according to access site: ≥250 s (6.86% versus 10.18%; odds ratio, 1.57; 95% confidence interval, 1.00-2.45; P=0.047) by femoral approach and ≥290 s (2.86% versus 5.43%; odds ratio, 2.24; 95% confidence interval, 1.05-4.44; P=0.027) by radial approach. Conclusions-In the TAO trial, peak procedural ACT ≥250 s was associated with increased bleeding risk in non-ST-segment-elevation acute coronary syndrome patients treated with unfractionated heparin plus GPIs. This threshold was increased to 290 s when performing radial approach. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT01076764.
A nticoagulation is administered in addition of antiplatelet drugs in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) to inhibit thrombin generation and activity. There is evidence that anticoagulation is effective in reducing the incidence of ischemic events in NSTE-ACS and that the combination with platelet inhibitor is more effective than either treatment alone. 1 Anticoagulants are used in NSTE-ACS patients to reduce thrombus-related events, particularly during percutaneous coronary intervention (PCI). Guidelines recommend shortening anticoagulation after revascularization to reduce bleeding complications 2 and to improve clinical outcomes. 3, 4 Despite a narrow therapeutic window, unfractionated heparin (UFH) remains a widely used anticoagulant in NSTE-ACS in the context of short delays to coronary angiography and short hospital stays. Measurement of activated clotting time (ACT) at the time of PCI in the catheterization laboratory has been proposed to reduce periprocedural ischemic or bleeding events. 5, 6 This strategy is based on several retrospective analyses showing an association between ACT values and thrombotic 7, 8 or bleeding 9 outcomes. Conversely, more recent analyses have found no association between ACT and the risk of bleeding 10 or ischemic 11, 12 events. Therefore, the value of using ACT to guide UFH dosing in patients undergoing PCI remains debated.
Moreover, few data are available about the value of ACT in patients undergoing PCI and receiving GPIs (glycoprotein IIb/IIIa inhibitors). A recent analysis of the FUTURA/ OASIS-8 trial (Fondaparinux Trial With Unfractionated Heparin [UFH] During Revascularization in Acute Coronary Syndromes [ACS] ) showed that in patients not receiving planned GPIs, an ACT value ≤300 s was associated with an increased risk of ischemic complications, but that ACT did not predict hemorrhagic complications. 13 Conversely, no relationship was found between ACT and ischemic or hemorrhagic complications in patients treated with GPIs. This subgroup analysis was, however, underpowered. Using the data from the large recent TAO trial (Treatment of Acute coronary syndromes with Otamixaban), 14 we aimed to analyze the relationship between ACT and outcomes in NSTE-ACS patients undergoing PCI with planned GPI treatment.
Methods

Study Population
The TAO trial was designed as a superiority trial to compare the clinical efficacy and safety of otamixaban with that of UFH plus eptifibatide at the start of PCI in patients with NSTE-ACS with a planned invasive strategy. The data, analytic methods, and study materials have already been published for other researchers to replicate the results. 15 The study enrolled 13 229 moderate to high-risk NSTE-ACS patients, and the primary efficacy outcome was the composite of all-cause death or new myocardial infarction (MI) through day 7. The main exclusion criteria were revascularization procedure already performed for the qualifying event; acute ST-segment-elevation myocardial infarction; receipt of a therapeutic dose of injectable anticoagulant for >24 hours before randomization; or treatment with abciximab during the index episode. The control arm included 5466 patients receiving UFH and downstream eptifibatide. There were no differences for the primary efficacy outcome between the 2 groups. The primary safety outcome of Thrombosis In Myocardial Infarction major or minor bleeding through day 7 was increased with otamixaban.
14 The present analysis focused on the 3554 NSTE-ACS patients receiving UFH plus downstream eptifibatide who underwent PCI (which was, per protocol, to be performed within 36 hours of randomization and at the latest on day 3). All patients provided written informed consent. In every participating country, institutional review boards in accordance with local guidelines approved the study.
Study Treatments
Patients received UFH (60 IU/kg intravenous bolus [maximum 4000 IU] followed by an infusion of 12 IU/kg per hour [maximum 1000 IU/h]) as soon as possible after randomization and continued until the end of PCI. Blinded treatment with eptifibatide was initiated at the start of PCI, with a 180 μg/kg bolus immediately before PCI, followed by a continuous infusion of 2 μg/kg per minute, and a second 180 μg/kg bolus 10 minutes later. For patients with a creatinine clearance lower than 50 mL/min, the infusion rate was reduced to 1 μg/kg per minute. The infusion was to be given for 18 to 24 hours after PCI or until hospital discharge, whichever came first, with an option for blinded bailout eptifibatide (placebo for those originally randomized to UFH plus eptifibatide) to be given only when deemed necessary by the investigator (who remained blinded to all study drugs). If angiography did not lead to PCI, eptifibatide was not administered, and the duration of anticoagulation with UFH was left to the investigator's discretion, but could not exceed 4 days or to hospital discharge. In addition to the blinded study medication, all randomized patients were to receive both aspirin and an oral adenosine diphosphate receptor antagonist (eg, clopidogrel, prasugrel, ticagrelor) in accordance with local label or guidelines.
ACT Measurement
ACT guidance was performed in the local laboratory at the time of angiography or PCI under UFH infusion and before eptifibatide treatment and the ACT value was to be ≥200 s. If ACT value was <200 s at the time of PCI, additional UFH bolus doses (10-40 UI/kg) were administered according to protocol (Table I in the Data Supplement). In case of prolonged PCI, ACT could be repeated during the PCI. We analyzed the ACT before PCI (last measurement performed before the beginning of the PCI, usually the first value) and the peak ACT (the highest value of ACT measured during the whole procedure). In order for the investigators to remain blinded, all ACTs were performed using an encrypted device (Hemochron Signature Elite machine, International Technidyne Corp). In case of intraprocedural thrombotic complications, ACT was to be adjusted to at least 250 s according to the protocol.
We chose to analyze peak ACT (rather than preprocedural ACT) when seeking a relationship between ACT and bleeding. This is in keeping with the literature 10, 12 and seems more appropriate than analyzing the baseline value. Conversely, we analyzed baseline ACT when seeking a relation with periprocedural ischemic outcomes because it is well-documented that the latter typically induce rebolusing
WHAT IS KNOWN
• Activated clotting time guidance is widely used to monitor unfractionated heparin dosing during percutaneous coronary intervention.
• The value of activated clotting time in predicting ischemic and hemorrhagic complications in patients treated with GPIs (glycoprotein IIb/IIIa inhibitors) is controversial in the modern era.
WHAT THE STUDY ADDS
• In non-ST-segment-elevation acute coronary syndrome patients treated with unfractionated heparin plus systematic use of GPIs:
• Activated clotting time ≥200 s does not predict ischemic complications;
• Peak activated clotting time ≥250 s predicts hemorrhagic complications in non-ST-segment-elevation acute coronary syndrome patients treated by unfractionated heparin plus GPIs;
• This threshold could be increased to 290 s when performing radial approach. of heparin and therefore the peak ACT value may be a consequence rather than a cause of an ischemic event.
Outcomes
The efficacy outcome of the present analysis was the composite of all-cause death, MI, stent thrombosis, procedural thrombotic complication during PCI, and stroke from randomization to day 7, according to ACT value before PCI. This broad composite outcome was chosen to capture ischemic and thrombotic outcomes with optimal sensitivity. To explore the relation of ACT values to more specific ischemic outcomes in a shorter time window, sensitivity analyses focusing on cardiovascular death and MI during hospitalization (at 4 days) were also performed. MIs were categorized according to the 2007 universal definition. 16 Stent thrombosis was categorized according to the Academic Research Consortium classification. 17 The primary safety outcome was the occurrence of bleeding complications according to Bleeding Academic Research Consortium (BARC types 2-5), measured from randomization through day 7 according to the peak procedural ACT achieved during PCI. The BARC classification was selected for this analysis because it is objective, validated, and more sensitive in predicting clinically meaningful events than the Thrombosis In Myocardial Infarction classification.
18,19
Statistical Methods
Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). Baseline patient and procedure characteristics are presented in categories according to last ACT before PCI. The categories were ACT <200 s, ACT ≥200 s, and <250 s; ACT ≥250 s and <300 s; ACT ≥300 s. Continuous data are summarized by means and SDs. Categorical variables are reported as frequencies and percentages. Correlation coefficient between ACT value before PCI and UFH dose was calculated using Spearman rank correlation coefficient. Logistic regression modeling was used to identify odds ratios and 95% confidence intervals for the effects of peak ACT on outcomes by fitting a restricted cubic spline function with knots at the 5th, 35th, 65th, and 95th percentiles. The nonlinear relationship between ACT and outcomes was assessed by testing the restricted cubic spline term introduced in the logistic model equation. Median value was chosen as the reference for all spline plots. Ischemic outcomes were analyzed according to last value of ACT before PCI, and bleeding outcomes were analyzed according to peak ACT during PCI (highest value during PCI). To identify predictive ACT thresholds for ischemic and bleeding events, ACTs were categorized using cut points ranging from 200 to 350 s in 10 s increments. Subgroup analyses using the same methods were performed according to PCI access site (femoral versus radial). Receiver operating characteristic curve analysis of peak ACT during PCI to predict bleeding (BARC 2-5) was performed, and area under the curve was determined. Optimal ACT threshold was estimated by Youden J statistics calculation. Logistic regression models comparing patients with ACT above versus below the threshold were adjusted for age, sex, diabetes mellitus, prior PCI, serum creatinine, systolic blood pressure, elevated biomarker at presentation, heart failure, heart rate, and body weight. For bleeding complications, radial access and level of hemoglobin were also added to the model. A 2-tailed P<0.05 was considered statistically significant.
Results
Population Characteristics
Of 5466 patients enrolled into the UFH arm of the TAO trial, 3554 patients underwent PCI. ACT values measured using the Hemochron device were available at least once in 3275 patients. ACTs were either not performed, not recorded, or not analyzed because of technical reasons, or there were missing values in 279 patients. Figure 1 provides a schematic of the study.
ACT Results
Among the 3275 patients in whom ACT was measured with the Hemochron device, the median ACT before PCI value was 219 s. The 5th, 35th, 65th, and 95th percentiles were respectively 156, 208, 234, and 325 s. Using cut points <200 s and up to 300 s, 706 patients (21.6%) had ACT values <200 s; 1771 (54.1%) had values of 200 to 249 s; 520 (15.9%) had values of 250 to 299 s; 278 (8.5%) had values of ≥300 s. Patients' baseline characteristics according to ACT before PCI categories are detailed in Table 1 and according to peak ACT during PCI in Table II in the Data Supplement.
Correlation Between UFH Dose and ACT
There was no correlation (r=−0.02; P=0.24) between ACT at the time of PCI and UFH dose received before PCI (infusion administered after randomization+bolus).
Ischemic End Points and ACT Before PCI
Outcomes according to categories of ACT before PCI are presented in Table 2 (Table III in No relationship between ACT before PCI and ischemic complications was apparent (test for curvature, P=0.66). As the target ACT was ≥200 s, we sought to determine using 10 s increments in cut points ranging from 200 to 350 s whether there was a threshold of ACT below which the risk of an ischemic adverse outcome was increased and a minimum P value approach was performed. In this population, between 200 s and 350 s, there was no cut point associated with a significant P value for ischemic outcomes ( Table 2 . Spline curves of peak ACT on bleeding outcomes are presented in Figure 3 . The linear relationship between peak ACT and bleeding events was not significant (test for curvature P=0.07). A threshold of peak ACT above which the risk of bleeding increased was sought using incremental cut points of ACT ranging from 200 s to 350 s. Higher bleeding rates were seen in patients with peak ACT from 230 s and up to 270 s and the optimal threshold was 250 s (4.71% in patients with ACT <250 s versus 6.63% in patients with ACT ≥250 s; adjusted odds ratio, 1.58; 95% confidence interval, 1.1-2.25; P=0.01; Table 4 ). Using receiver operating characteristic curve analysis of peak ACT during PCI to predict bleeding, the area under the curve observed was poor (area under the curve=0.56) and the optimal ACT threshold was 230 s ( Figure  II in the Data Supplement).
Radial Versus Femoral Access Site
PCI by femoral access was performed in 1495 patients (47.5%) and by radial access in 1771 patients (54.1%). No difference in the primary ischemic end point was apparent between both groups: n=116 (7.8%) in the femoral group and n=117 (6.6%) in the radial group (P=0.23). Likewise, there was no difference in death (13 versus 11 deaths, respectively; P=0.85). There were more BARC 2-5 bleedings, in the femoral group (n=105, 7.0%) than in the radial group (n=52, 2.9%; P<0.0001). The optimal ACT threshold varied between both groups: using the femoral approach, higher bleeding rates were observed in patients with peak ACT ≥250 s (6.86% in patients with ACT <250 s versus 10.18% in patients with ACT ≥250 s; adjusted odds ratio, 1.57; 95% confidence interval, 1.00-2.45; P=0.047; Table 5 ), whereas using the radial approach, higher bleeding rates were observed in patients with peak ACT ≥290 s (2.86% in patients with ACT <290 s versus 5.43% in patients with ACT ≥290 s; adjusted odds ratio, 2.24; 95% confidence interval, 1.05-4.44; P=0.027; Table 6 ). Using a vascular closure device in the femoral group (n=790), an ACT >247 s was associated with increased bleeding. In patients undergoing femoral access without vascular closure device, increased bleeding was seen above an ACT of 203 s (n=705).
Discussion
In this post hoc analysis of the TAO trial, a large contemporary randomized trial of patients with NSTE-ACS treated by PCI, pre-PCI ACT in patients treated with UFH and GPIs did not predict ischemic events. Peak ACT predicted increased bleeding when ACT ≥230 s, with the optimal threshold being ≥250 s overall, and ≥290 s in those receiving radial access. The present analysis is the largest cohort to date from a single randomized trial with systematic blinded ACT measurements (n=3275 patients).
ACT Guidance and Ischemic Outcomes
Measurement of ACT in the catheterization laboratory at the time of PCI has been proposed to reduce periprocedural ischemic events. The results of the various studies about this subject seem conflicting. Several retrospective analyses where the dose of UFH was left to operator discretion have shown an inverse correlation between ACT values and ischemic events. 8 A pooled analysis of 6 randomized trials 7 totaling 5216 patients indicated that an ACT between 325 and 350 s was associated with fewer ischemic events. Because these studies, the risk of periprocedural thrombotic complications associated with PCI has decreased dramatically with procedural improvements and the use of potent adjunctive antiplatelet therapies. A recent study from the Mayo Clinic in 12 055 patients who underwent PCI found no independent association between ACT and in-hospital or 1-year ischemic events. 20 In a post hoc analysis of the FUTURA/OASIS-8 trial, an ACT ≤300 s was correlated with an increased risk of ischemic complications only in patients not receiving planned GPIs. In the present study, neither a linear correlation nor a threshold was found between ACT and ischemic events. The fact that ACT does not predict ischemic events in our population could be related to the impact of systematic GPIs administration reducing the rate of ischemic complications. However, the rate of the ischemic composite end point was high (7.15% of patients) suggesting that it is not because of lack of sensitivity. However, as the objective of the study was to obtain a value of ACT >200 s at the time of PCI, we cannot exclude that there exists a threshold <200 s which would predict an increased risk of ischemic events. Our results are in accordance with current guidelines. The American College of Cardiology/ American Heart Association guidelines favor systematic ACT measurement and recommend a given dosage of heparin to achieve therapeutic ACT up to 200 s in patients with planned GPIs (using Hemochron device).
13
5
ACT Guidance and Bleeding Outcomes
It has been clearly demonstrated that the risk of bleeding complications is strongly associated with worse outcomes in acute coronary syndromes. 3, 4 Several relatively old retrospective analyses where the dose of UFH was left to operator discretion had shown a correlation with bleeding outcomes. 9 Recent analyses have found no association between ACT and the risk of bleeding events. 10, 20 A pooled analysis of 8369 patients 11 reported a weak correlation between ACT value and hemorrhagic complications and results from the HORIZONS-AMI trial (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) 12 suggest that in patients with ST-segment-elevation myocardial infarction, peak procedural ACT does not have a substantial relationship with major bleeding, mortality, or major adverse cardiovascular events, although a lower peak ACT was associated with fewer cases of minor bleeding. Finally, the FUTURA/ OASIS-8 analysis 13 showed no correlation between ACT and bleeding outcomes.
Given these contradictory observations, the question of predictive value of ACT measurement in NSTE-ACS patients in the modern era of ACS is still unresolved as illustrated by the European Society of Cardiology and American Heart Association guidelines. 2, 5, 6, 21 The European Society of Cardiology guidelines for the management of NSTE-ACS mention that ACT can be used, 2 without providing a clear level of recommendation and evidence grade. The American College of Cardiology/American Heart Association guidelines on ST-segment-elevation myocardial infarction favor systematic ACT measurement and recommend a specific ACT target (using Hemochron device: 200-250 s with planned GP IIb/IIIa inhibitor, 300-350 s without). 5 The present study found that a peak procedural ACT of 250 s or more was associated with increased BARC type 2-5 bleeding in NSTE-ACS PCI patients treated by UFH and GPIs. All patients received standardized UFH treatment and there was no anticoagulation crossover. Moreover, blinded ACT measurements were integrated into an adjustment algorithm, which represents a key methodological strength, minimizing bias. Overall, the present results suggest that the ACT achieved during PCI in patients treated with GPIs should not exceed 250 s. However, as demonstrated by the receiver operating characteristic curve analysis ( Figure II in the Data Supplement), ACT value indicates a risk of bleeding but is not sufficient alone to accurately predict bleeding (which is a complex phenomenon influenced by multiple factors).
ACT Thresholds and Access Site
These results are derived from a cohort largely treated via radial artery access, which is likely to have reduced access site bleeding. Several trials have demonstrated a benefit of the radial approach compared with the femoral approach in ACS patients undergoing primary PCI with a reduction of access site complications. The RIVAL trial (Radial Versus Femoral Access for Coronary Intervention) showed a lower rate of local vascular complications when using the radial approach. 22 The MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX) randomized 8404 ACS patients undergoing invasive management between transradial or transfemoral access to perform PCI. Radial access reduced the risks of access site bleeding, vascular complications, and need for transfusion, but also importantly, mortality. 23 Observational studies concur with a greater safety of radial access. 24 In the present analysis, the ACT threshold predicting increased bleeding was higher for the radial than the femoral approach. Moreover, in the femoral access subgroup, the threshold is even lower when a femoral approach was performed without a vascular closure device. These results can help adjust clinical decision-making and intensity of anticoagulation according to the PCI access site.
Our analysis has several limitations. First, the TAO trial enrolled only patients with NSTE-ACS and all patients received heparin from randomization to PCI (without anticoagulation crossover) and were treated by GPIs during PCI (which is known to increase bleeding). The present results should not be extrapolated to patients without GPIs or to patients receiving a low dose of fondaparinux 13 (for which a prior analysis has already been performed) or low molecular weight heparin before PCI. Although it is true that GPIs were widely used in the 2010 s sometimes even systematically as in the TAO trial, recent guidelines 2, 25 recommend their use in patients with high-risk features and not adequately pretreated by P2Y12 inhibitors or during PCI in the bailout (in case of no-reflow or thrombotic complication). In contemporary practice, the use of GPIs has substantially declined and now ranges from 40% to as low as 5% of NSTE-ACS patients according to the most recent United States and European registries. [26] [27] [28] This emphasizes that the results of the present study only apply to a limited group of NSTE-ACS patients given the decline in-catheterization laboratory use of GPIs.
Likewise, the results of the present study do not apply to prasugrel-or ticagrelor-treated patients. The United States and European guidelines recommend the use of new P2Y12 inhibitors as the first line treatment if available or not contraindicated. 2, 5 However, the latest registry data available in the United States and in Europe show that clopidogrel remains widely used in current practice in ≈40% to 70% of NSTE-ACS patients. [26] [27] [28] [29] [30] Second, this analysis was performed only in patients with ACT guided by the Hemochron device. The results should therefore not be extrapolated to other devices. However, the Hemochron is the most widely used device. Finally, even if the present data derived from a carefully controlled randomized trial, more than one-half of the patients were outside of the target ACT recommended by the protocol, highlighting the difficulties of achieving reliable optimal anticoagulation during PCI. It is likely that in routine clinical practice, a greater proportion of patients fall outside the target window.
Conclusions
In the TAO trial, we did not observe any relationship between ACT values and ischemic outcomes in NSTE-ACS patients treated with UFH plus GPIs undergoing PCI.
Conversely, a peak procedural ACT ≥250 s was associated with increased bleeding risk. This threshold was increased to 290 s when performing radial approach.
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